GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $1,569,074.38 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 22,307 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $70.34, for a total transaction of $1,569,074.38. Following the transaction, the chief executive officer now owns 60,011 shares of the company’s stock, valued at $4,221,173.74. This trade represents a 27.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $143,456.40.
• On Monday, September 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total value of $121,287.87.

GeneDx Trading Up 9.2 %

NASDAQ WGS opened at $78.71 on Friday. GeneDx Holdings Corp. has a 12 month low of $1.41 and a 12 month high of $89.11. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company has a 50-day moving average of $59.61 and a 200-day moving average of $39.55. The company has a market cap of $2.16 billion, a P/E ratio of -25.31 and a beta of 2.11.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. During the same period last year, the company posted ($0.82) EPS. The business’s quarterly revenue was up 44.3% on a year-over-year basis. As a group, equities analysts predict that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

A number of hedge funds have recently made changes to their positions in the business. Oracle Investment Management Inc. raised its stake in shares of GeneDx by 531.7% during the first quarter. Oracle Investment Management Inc. now owns 1,126,607 shares of the company’s stock valued at $10,286,000 after purchasing an additional 948,253 shares during the period. Driehaus Capital Management LLC bought a new stake in shares of GeneDx in the second quarter worth $11,335,000. Fred Alger Management LLC acquired a new stake in GeneDx in the third quarter valued at $16,731,000. Assenagon Asset Management S.A. bought a new stake in shares of GeneDx in the 2nd quarter worth about $9,575,000. Finally, Divisadero Street Capital Management LP acquired a new stake in shares of GeneDx in the 2nd quarter valued at about $5,886,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Wall Street Analysts Forecast Growth

WGS has been the topic of several recent research reports. Wells Fargo & Company upped their price objective on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group upped their target price on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Craig Hallum boosted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. BTIG Research raised their target price on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, TD Cowen lifted their target price on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and an average price target of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.